Latvia vs Trinidad and Tobago: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Latvia
97.0%
in 2025
Trinidad and Tobago
97.0%
in 2025
Latvia rank
17th
Trinidad and Tobago rank
17th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Latvia
- Trinidad and Tobago
How they compare
Latvia currently reports 97.0% against 97.0% in Trinidad and Tobago, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Trinidad and Tobago ahead.
Latvia ranks 17th and Trinidad and Tobago ranks 17th of 194 countries.
Across the 3 decades both report, Latvia averaged higher in 1 and Trinidad and Tobago in 1.
Head to head by decade
| Decade | Latvia | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 72.6% | 68.4% | 4.2% | Latvia |
| 2020s | 92.3% | 94.3% | 2.0% | Trinidad and Tobago |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Latvia or Trinidad and Tobago?
- Latvia, at 97.0% against 97.0% in Trinidad and Tobago as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Latvia and Trinidad and Tobago?
- 0.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Trinidad and Tobago?
- 18 years are reported by both, from 2008 to 2025.
- How do Latvia and Trinidad and Tobago rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Latvia ranks 17th and Trinidad and Tobago ranks 17th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.